5-Methoxytryptamine hydrochloride powder 98%

• Powder: Yes
• Customized: Customized
• Certification: ISO 9001
• Suitable for: Adult
• State: Solid
• Purity: >97%
• Transport Package: 1.1 Kilogram Per Aluminum Foil Bag with One Plast
• Specification: 98%
• Trademark: SOST
• Origin: China
• Production Capacity: 500 Tons/Month

Product Description

1.Basic Information

Product name	5-Methoxytryptamine hydrochloride
Appearance	White crystal powder
CAS No	66-83-1
Molecular formula	C11H15ClN2O
Molecular weight	226.703
Boiling point	380ºC at 760 mmHg
Melting point	246 °C
Flash point	183.6°C
Density	1.171 g/cm3
Storage	2-8°C, sealed away from light
Application	Raw materials and intermediates, intermediates of "melatonin".

 

2.COA:

  CERTIFICATE OF ANALYSIS                                                  

Product name	5-Methoxytryptamine hydrochloride	Country of Origin	China
Batch Size	500KG	Batch Number	20220508
Manufacture Date	May 8, 2022	Expiry Date	May 7, 2023

 

ITEM	STANDARD	RESULT
Identification	Positive reaction	Conform
Loss on drying	0.5% MAX	0.04%
Sulphated Ash	0.5% MAX	0.06%
Color test	0.5% Reference solution	conform
Heavy metal	20PPM MAX	conform
Assay(HPLC)	98.0% MIN	99.12%

Conclusion: Comply with the requirements of enterprise standard.

3.Function
5-Methoxytryptamine is a tryptamine derivative that is closely related to the neurotransmitters melatonin and serotonin. It acts as a full agonist at the 5-HT1, 5-HT2, 5-HT4, 5-HT6 and 5-HT7 receptors, but has no affinity for the 5-HT3 receptor. It is a full agonist at the 5-HT1, 5-HT2, 5-HT4, 5-HT6 and 5-HT7 receptors. 5-Methoxytryptamine hydrochloride has similar efficacy to 5-methoxytryptamine. However, compared with 5-methoxytryptamine, 5-methoxytryptamine hydrochloride has stronger stability and better water solubility.

4.Application
The protective effect of 5-methoxytryptamine, a metabolite of melatonin, in human keratinocytes against ultraviolet B (UVB) has been investigated. 5-Methoxytryptamine as an agonist has been used in pharmacological studies of serotonin-1 receptors.
Reactants for the preparation of:
1. Carboline disaccharide domain of shishijimicin A
2. Melatonin analogs for lowering intraocular pressure
3.5-HT4 receptor ligands
4. Inhibitors of sortase A and isocitrate lyase
5. Therapeutic agents for the treatment of ischemia/reperfusion (I/R) injury
6. Agents for the treatment of human papillomavirus infection
7. Manzamine analogs are used to control neuroinflammation and brain infections
8. Inhibitors of pro-inflammatory cytokines
9. Tacrine-melatonin hybrids as multifunctional drugs for Alzheimer's disease